Freedom Investment Management Inc. Decreases Holdings in Johnson & Johnson $JNJ

Key Points

• Freedom Investment Management Inc. has reduced its holdings in Johnson & Johnson by 13.7%, now owning 8,760 shares valued at approximately $1.45 million.
• Analysts have raised their target prices for Johnson & Johnson's stock, with Citigroup and Barclays increasing targets to $200.00 and $176.00, respectively, indicating a favorable outlook for the company.
• Johnson & Johnson reported earnings of $2.77 per share and revenues of $23.74 billion, surpassing analyst estimates and showing a 5.8% year-over-year revenue increase.

Freedom Investment Management Inc. decreased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 13.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,760 shares of the company's stock after selling 1,396 shares during the period. Freedom Investment Management Inc.'s holdings in Johnson & Johnson were worth $1,453,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. Independent Franchise Partners LLP raised its holdings in Johnson & Johnson by 2.1% during the 1st quarter. Independent Franchise Partners LLP now owns 5,302,536 shares of the company's stock valued at $879,373,000 after buying an additional 108,065 shares during the last quarter. ICONIQ Capital LLC grew its position in shares of Johnson & Johnson by 114.0% in the 1st quarter. ICONIQ Capital LLC now owns 10,091 shares of the company's stock worth $1,673,000 after buying an additional 5,375 shares during the period. Southeast Asset Advisors LLC grew its position in shares of Johnson & Johnson by 3.2% in the 1st quarter. Southeast Asset Advisors LLC now owns 39,104 shares of the company's stock worth $6,485,000 after buying an additional 1,221 shares during the period. AIMZ Investment Advisors LLC boosted its stake in Johnson & Johnson by 3.5% in the 1st quarter. AIMZ Investment Advisors LLC now owns 14,563 shares of the company's stock worth $2,415,000 after purchasing an additional 498 shares in the last quarter. Finally, Smartleaf Asset Management LLC boosted its stake in Johnson & Johnson by 10.4% in the 1st quarter. Smartleaf Asset Management LLC now owns 37,066 shares of the company's stock worth $6,068,000 after purchasing an additional 3,496 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Wall Street Analyst Weigh In

JNJ has been the topic of several research analyst reports. Citigroup upped their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a research note on Thursday. Guggenheim reissued a "neutral" rating and issued a $167.00 target price (up from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Barclays increased their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Finally, Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $176.29.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $179.0980 on Monday. The stock's fifty day moving average price is $163.48 and its 200-day moving average price is $159.30. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $181.16. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The firm has a market cap of $431.33 billion, a P/E ratio of 19.15, a P/E/G ratio of 2.28 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the previous year, the firm earned $2.82 earnings per share. The company's revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson & Johnson's payout ratio is presently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.